AstraZeneca has admitted in court filings that its Covishield Covid-19 vaccine may, in rare cases, lead to thrombosis with thrombocytopenia syndrome (TTS), a serious condition involving blood clotting and low platelet levels. This acknowledgment emerged amid a class-action lawsuit initiated in April 2021, casting the pharmaceutical giant into legal scrutiny.
Initiated by Jamie Scott, who suffered permanent brain damage linked to TTS after receiving the AstraZeneca vaccine, the lawsuit underscores the grave consequences of this uncommon side effect, shedding light on the struggles of numerous families affected by similar tragic outcomes.
Developed in collaboration with Oxford University, the vaccine garnered global attention under the names Covishield and Vaxzevria. AstraZeneca’s court documents, filed with the English High Court, now explicitly mention the potential risk of TTS, marking a significant juncture in the legal battle.
Despite this admission, AstraZeneca maintains the vaccine’s effectiveness in preventing Covid-19, asserting that the benefits of vaccination outweigh the risks for the majority. However, the company could face substantial compensation claims if found liable for vaccine-related harm. The legal developments in the UK hold implications beyond borders, potentially prompting action from other affected parties, including those in India, where the vaccine was distributed by the Serum Institute of India in collaboration with AstraZeneca.
Post Your Comments